Latest News
Psychobiotics and Depression: Exploring the Gut–Brain Connection
Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...
Latest News
Online Prescribing Is Moving Faster Than Regulation
Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...
Clinical Trials Roundup | 25 September 2026
The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...
Rethinking the Office: The Need for Healthier Buildings
For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...
When Life Sciences Compliance Problems Are Really Operations Problems
When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
GroYourBiz Honours Canadian Clinical Leaders as “Champions of Change”
GroYourBiz (GYB), a leading organisation supporting female senior leaders and women-owned businesses, is proud to announce the recipients of its 2026 Champion of Change Award, three exceptional clinical leaders whose innovation and determination are transforming...
Weekly News Roundup | 22 June 2026
Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...
AVITA Medical Presents RECELL GO U.K. Clinical Data at BBA Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells...
Clinical Trials Roundup | 19 June 2026
The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery By 78.5% at Leeds Teaching Hospitals A pilot involving 189 patients at Leeds Teaching Hospitals using nasal photodisinfection prior to complex brain procedures performed through the nose has led...
Beyond the Injection: The Future of Holistic GLP-1 Care
The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....
Biotech IPO Surge: 2026’s First Half Beats 2025
Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...
Why AI May Increase Cognitive Burden Before Reducing It
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
The Seduction of Ease: Burnout, AI, and Human Leadership in Life Sciences
Life sciences exist to do something extraordinary. Their applied solutions seek to understand biology and improve health and the quality of life for humans, animals, and plants. That is not a small mission; at its core, it is deeply human. It is the kind of mission...
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Improving Oncolytic Virus Development for Cancer Immunotherapy Research
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Will Artificial Intelligence Replace Medical Science Liaisons?
What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...
GroYourBiz Honours Canadian Clinical Leaders as “Champions of Change”
GroYourBiz (GYB), a leading organisation supporting female senior leaders and women-owned businesses, is proud to announce the recipients of its 2026 Champion of Change Award, three exceptional clinical leaders whose innovation and determination are transforming...
Weekly News Roundup | 22 June 2026
Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...
AVITA Medical Presents RECELL GO U.K. Clinical Data at BBA Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells...
Clinical Trials Roundup | 19 June 2026
The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery By 78.5% at Leeds Teaching Hospitals A pilot involving 189 patients at Leeds Teaching Hospitals using nasal photodisinfection prior to complex brain procedures performed through the nose has led...
Beyond the Injection: The Future of Holistic GLP-1 Care
The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....
Biotech IPO Surge: 2026’s First Half Beats 2025
Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...
Why AI May Increase Cognitive Burden Before Reducing It
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
The Seduction of Ease: Burnout, AI, and Human Leadership in Life Sciences
Life sciences exist to do something extraordinary. Their applied solutions seek to understand biology and improve health and the quality of life for humans, animals, and plants. That is not a small mission; at its core, it is deeply human. It is the kind of mission...
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Improving Oncolytic Virus Development for Cancer Immunotherapy Research
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Will Artificial Intelligence Replace Medical Science Liaisons?
What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...
Featured Articles
Further News
GLP-1 Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026
Last updated 18 October 2026. Generic semaglutide is now on sale in India and Canada, and France began reimbursing obesity treatment on 15 June. GLP-1 uptake by country has rarely looked so uneven. Glucagon-like peptide-1 (GLP-1) receptor agonists began as type 2...
AI’s Next Leap in Biopharma: From Acceleration to Intelligence in Partnership
Artificial intelligence has already changed the rhythm of discovery in biopharma. Algorithms can screen millions of molecules, identify trial candidates, and forecast supply chains with extraordinary speed. Yet speed is not the same as progress. The next chapter of AI...
Weekly News Roundup | 15 June 2026
Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...
What GLP-1 Patients Don’t Know About Muscle Loss and Why It Matters
GLP-1 receptor agonists are transforming obesity treatment. But the clinical conversation about lean muscle preservation is lagging behind the prescribing rate, and that gap has real consequences for patients, says Omar el-Gohary. There is a version of the GLP-1...
Why Europe’s Precision Oncology Trials Keep Stalling
Precision medicine works when the right biomarker test reaches the right patient in time. In Europe, the regulatory plumbing is making that harder than it should be. At the 16th Clinical Biomarkers & CDx Summit in London in March 2026, I discussed lessons from MDx...
Complement Inhibitor Setback: Sanofi Halts CIDP Study
Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...
Clinical Trials Roundup | 12 June 2026
Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...
Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026
The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...
The Case for Agility: Why Biopharma Must Embrace Adaptive Trial Designs
For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...
GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race
Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...
FDA Drug Approval Decisions: June and July 2026
The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...
Importance of Targeted Radiotherapeutics in Treating CNS Cancers
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.